Risk in Dosing Regimens for 25-OH Vitamin D Supplementation in Chronic Haemodialysis Patients

被引:5
作者
Albalate, M. [1 ]
de la Piedra, C. [2 ]
Ortiz, A. [3 ]
Hernandez Perez, J. [3 ]
Rubert, M. [2 ]
Perez Garcia, R. [1 ]
Zazo, P. [2 ]
Nieto, L. [4 ]
de Sequera, P. [1 ]
Egido, J. [3 ]
机构
[1] Hosp Univ Infanta Leonor, Serv Nefrol, ES-28031 Madrid, Spain
[2] Autonoma Univ IIS Fdn Jimenez Diaz, Serv Bioquim, Madrid, Spain
[3] Autonoma Univ IIS Fdn Jimenez Diaz, Serv Nefrol, Madrid, Spain
[4] Ctr Dialisis Santa Engracia FRIAT, Madrid, Spain
来源
NEPHRON CLINICAL PRACTICE | 2012年 / 121卷 / 3-4期
关键词
Haemodialysis; 25-hydroxyvitamin D; Calcium; Phosphorus; PTH; CHRONIC KIDNEY-DISEASE; HIGH-DOSE CHOLECALCIFEROL; MINERAL METABOLISM; D DEFICIENCY; ERGOCALCIFEROL; BONE;
D O I
10.1159/000345148
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction: 25-OH vitamin D (25-OHvitD) insufficiency or deficiency should be treated in haemodialysis (HD) patients, although the 25-OHvitD target, drug or dosing regimens are unclear. Aims: To describe factors associated with 25-OHvitD levels in HD patients and to assess the effect of three dosing regimens to supplement 25-OHvitD (calcifediol) on serum calcium (Ca), phosphate (P), parathyroid hormone (PTH), 25-OHvitD and 1,25-OHvitD. Methods: Two hundred and seventeen patients from three HD units were studied. Demographic and biochemical data were collected at baseline. Two different 25-OHvitD assays were used. One hundred and sixty-seven patients were treated with various calcifediol dosing regimens. The same biochemical determinations were repeated after 3 months of treatment. Results: At baseline, 12.9% of patients had 25-OHvitD < 10 ng/ml. In multivariate linear regression, the season (lower in winter) and the assay method were determinants of 25-OHvitD concentration. Following calcifediol supplementation, 25-OHvitD, calcium and phosphate increased, while PTH diminished with statistical significance. After treatment, there were positive correlations between 25-OHvitD and Ca (r = 0.28, p < 0.0001) or 1,25-OHvitD (r = 0.75, p < 0.0001) that were not observed in the baseline dataset. High concentrations of post-treatment 25-OHvitD were associated with higher 1,25-OHvitD levels. Calcemia increased more in those treated with concomitant active vitamin D or those having suppressed baseline PTH, while PTH decreased more in those having above-target PTH levels. Conclusions: Standardisation of methods to determine 25-OHvitD blood levels is needed. In HD patients, calcifediol increased 25-OHvitD, calcemia and phosphatemia and lowered PTH. Caution should be exercised with the higher calcifediol dosing regimens, especially in patients with suppressed PTH or on vitamin D receptor activators. Copyright (C) 2012 S. Karger AG, Basel
引用
收藏
页码:C112 / C119
页数:8
相关论文
共 29 条
[1]  
[Anonymous], REV ESP ENFER MET S1
[2]   Prevalence of vitamin D [25(OH)D] deficiency and effects of supplementation with ergocalciferol (vitamin D2) in stage 5 chronic kidney disease patients [J].
Blair, Debra ;
Byham-Gray, Laura ;
Lewis, Emily ;
McCaffrey, Susan .
JOURNAL OF RENAL NUTRITION, 2008, 18 (04) :375-382
[3]   25-Hydroxyvitamin D levels in prevalent Australian dialysis patients [J].
Clayton, Philip ;
Singer, Richard .
NEPHROLOGY, 2009, 14 (06) :554-559
[4]   Defective renal maintenance of the vitamin D endocrine system impairs vitamin D renoprotection: a downward spiral in kidney disease [J].
Dusso, Adriana S. ;
Tokumoto, Masanori .
KIDNEY INTERNATIONAL, 2011, 79 (07) :715-729
[5]   State-of-the-Art Vitamin D Assays: A Comparison of Automated Immunoassays with Liquid Chromatography-Tandem Mass Spectrometry Methods [J].
Farrell, Christopher-John L. ;
Martin, Steven ;
McWhinney, Brett ;
Straub, Isabella ;
Williams, Paul ;
Herrmann, Markus .
CLINICAL CHEMISTRY, 2012, 58 (03) :531-542
[6]  
Food and Nutrition Board Institute of Medicine, 2010, DIETARY REFERENCE IN
[7]   PLASMA VITAMIN-D METABOLITE CONCENTRATIONS IN CHRONIC-RENAL-FAILURE - EFFECT OF ORAL-ADMINISTRATION OF 25-HYDROXYVITAMIN-D3 [J].
HALLORAN, BP ;
SCHAEFER, P ;
LIFSCHITZ, M ;
LEVENS, M ;
GOLDSMITH, RS .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1984, 59 (06) :1063-1069
[8]   Optimal Vitamin D Status [J].
Heaney, Robert P. .
JOURNAL OF BONE AND MINERAL RESEARCH, 2009, 24 (04) :755-755
[9]   Vitamin D deficiency [J].
Holick, Michael F. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (03) :266-281
[10]   Evaluation, Treatment, and Prevention of Vitamin D Deficiency: an Endocrine Society Clinical Practice Guideline [J].
Holick, Michael F. ;
Binkley, Neil C. ;
Bischoff-Ferrari, Heike A. ;
Gordon, Catherine M. ;
Hanley, David A. ;
Heaney, Robert P. ;
Murad, M. Hassan ;
Weaver, Connie M. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (07) :1911-1930